|
Patent landscape, scope, and claims: |
United States Patent 8,415,345: Scope, Claims Construction, and US Patent Landscape for Melanoma Treatment
What does US 8,415,345 claim in scope?
US Drug Patent 8,415,345 claims a large Markush-style chemical genus defined by Formula (I) plus dependent refinements covering narrower sub-genera, pharmaceutical compositions, and use in melanoma, including V600E metastatic melanoma. The claim set as provided contains:
- Independent claim 1: genus of compounds of Formula (I) and pharmaceutically acceptable salts.
- Dependent claims 2–9: structural narrowing by restricting subsets of variables (e.g., R1 choices, Ring A selection, Q-position substitution patterns, and Q4 constraints for intermediate sub-formulas).
- Independent claim 10: pharmaceutical composition.
- Independent claim 11: method of treating melanoma in humans using claim 1 compounds.
- Dependent claim 14: metastatic melanoma with V600E mutation context.
- Independent claim 12–13: processes for preparing claim 1 compounds via specified intermediates and transformations.
Claim structure overview (from the text provided)
| Claim |
Category |
What it covers |
| 1 |
Composition-of-matter (genus) |
Compounds of Formula (I), including salts |
| 2–9 |
Dependent composition refinements |
Restricts R1, Ring A, Q pattern, and Q4 in sub-formulas |
| 10 |
Composition-of-matter (formulation) |
Pharmaceutical composition with carrier/diluent/excipient |
| 11 |
Method-of-use |
Treating melanoma by administering a therapeutically effective amount |
| 14 |
Dependent method refinement |
Metastatic melanoma with V600E mutation |
| 12–13 |
Process claims |
Synthesis using defined intermediates/formulae |
How broad is the Formula (I) chemical genus?
Claim 1’s Formula (I) is broad by design. It combines multiple independently variable structural elements:
- Substitution count control:
- a = 0, 1, 2 or 3 (degree of substitution on Ring A framework in the way Formula (I) is defined).
- Multiple substituent classes on aromatic/heteroaromatic elements:
- R1 supports halo, alkyl, haloalkyl, OR6, CO2R6, NR6R7, and CN.
- Each R1 is independently selected, enabling many regio- and pattern-variants.
- Ring A is selected from:
- C3-6 cycloalkyl, phenyl, 5–6 membered heterocycle, or 5–6 membered heteroaryl, with 1 or 2 heteroatoms (N, O, S).
- Q positions define the “core substitution pattern”:
- Q1–Q4 each is CH, C–R2, or N, with the constraint that not more than one of Q1–Q4 is N.
- R2 is selected from halo, alkyl, haloalkyl, OR6 (per R2 definition in claim 1).
- Linker heteroatom W is O or S (W is —O— or —S—).
- R3 provides further expansion:
- Includes H, alkyl, haloalkyl, -alkylene-OH, NR6R7, C3-6 cycloalkyl, -alkylene-C(O)-OH, -alkylene-NH2, Het, with optional substitution on R3C3-6 cycloalkyl using a long list (halo, C1-3alkyl, OH, O-alkyl, oxo, sulfonyl variants, amino/amido-like choices).
- R4 and R8 expand the distal substituent architecture:
- R4 is H, alkyl, haloalkyl, alkenyl, OR6, R5-OR6, R5-CO2R6, R5-SO2R6, R5-Het, R5-C(O)-Het, N(H)R8, N(CH3)R8, or R5-NR6R7.
- R5 is C1-4 alkylene.
- R6/R7 are small modifiable units (H, alkyl, haloalkyl, and acyl-type: —C(O)-alkyl and —C(O)-cycloalkyl in claim 1).
- R8 allows many functional classes: alkyl (optionally OH), haloalkyl, cycloalkyl, Het2, OR6, acyls (C(O)2R6), urea/amides (C(O)NR6R7, N(H)C(O)-R6, N(H)C(O)-R5-OR6, etc.), sulfonamides (S(O)2R6), cyano, and cyano-methyl.
This combination creates a very large chemical search space even before considering the optional substitution counts on the cycloalkyl and Het groups.
Breadth compression points (constraints that limit the genus)
The main “hard constraints” within claim 1 are:
- Only one N allowed among Q1–Q4 (“not more than one” of those positions is N).
- Ring sizes fixed: Ring A is C3-6 cycloalkyl or 5–6 membered heterocycle/heteroaryl; Het2 is 4–6 membered heterocycle.
- R5 size fixed: C1-4 alkylene.
- Substituent optionality limited to 1 or 2 substituents on specified cycloalkyl fragments (R3C3-6cycloalkyl and R8C3-6cycloalkyl).
Practical genus scale indicator
Even with those constraints, claim 1 covers:
- Multiple ring classes,
- Multiple heteroatom linkers (O vs S),
- Multiple substitution sets (R1, R2, R4, R8),
- Multiple functional handles relevant to solubility and binding (OR6, CO2R6, NR6R7, CN, sulfone/sulfonamide classes).
What do dependent claims narrow?
Dependent claims 2–9 target specific subsets of the Markush variables and therefore carve out narrower structural “bands” inside the already broad genus.
Dependent claims (2–9) mapping
| Claim |
Narrowing mechanism |
What changes vs claim 1 |
| 2 |
Restricts R1 |
R1 limited to halo, alkyl, haloalkyl, OR6 (removes CO2R6, NR6R7, CN from R1 choices in this dependent claim) |
| 3 |
Restricts Ring A |
Ring A limited to phenyl, 5–6 membered heterocycle, or 5–6 membered heteroaryl (removes C3–6 cycloalkyl from this subset) |
| 4 |
Restricts Q pattern |
Each of Q1–Q4 is CH or C–R2 and at least two of Q1–Q4 are CH (removes N from Q1–Q4 in this dependent claim via explicit “is CH/C–R2”) |
| 5 |
Restricts R2 |
R2 limited to halo or C1–3 alkyl (removes OR6 and haloalkyl from the R2 options stated here) |
| 6 |
Restricts Q1–Q3 and Q4 |
Q1–Q3 are CH, and Q4 is C–F or C–Cl |
| 7–9 |
Sub-formulas with Q4 constraint |
Claims describe formula (I-iii-a) and (I-iii-b) with Q4 = CH or C–R2, signaling two closely related structural sub-types |
What this means for claim construction leverage
- The dependent claims supply structure-anchored fallback positions. In infringement or validity analysis, they function as narrower ways to match or distinguish suspect compounds, especially where an accused structure differs in:
- R1 substitution types (e.g., CN vs OR6),
- The presence/absence of N at Q positions,
- R2 functional class (halo vs OR6),
- Q4 specific identity (C–F/C–Cl in claim 6).
How does the patent translate chemistry into melanoma treatment claims?
Method-of-use scope (claim 11 and claim 14)
- Claim 11: method for treating melanoma in a human using a therapeutically effective amount of a claim 1 compound.
- Claim 14: narrows melanoma to metastatic melanoma with a mutation encoding V600E.
This creates a therapeutic use chain:
- Genus compound (claim 1) → any melanoma treatment (claim 11) → V600E metastatic melanoma (claim 14).
Method-of-use typical infringement markers
In practice, method-of-use claims require:
- A claimed compound or a compound falling within the Markush scope,
- Administration in humans for treating melanoma,
- For claim 14, context consistent with V600E metastatic melanoma.
What do the formulation and process claims add?
Pharmaceutical composition claim (10)
- Claim 10: “A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier, diluent or excipient.”
This is a standard dependent-independent formulation claim with typical breadth across dosage forms and excipient sets.
Synthesis/process claims (12–13)
- Claim 12: reacting a compound of formula (VIII) (R10 is halo or thiomethyl) with:
- (i) molecular hydrogen,
- (ii) an alkyl metal reagent or alkenyl metal reagent,
- (iii) an alcohol, or
- (iv) a compound of formula (IX): N(Ra)-R8 (Ra = H or CH3),
to prepare a compound of formula (I).
- Claim 13: reacting a compound of formula (XVIII) with a compound of formula (VII) to prepare formula (I).
Business implication: process claims can be leveraged defensively in licensing negotiations when competitors attempt to design around structure while keeping similar synthesis routes, though enforcement depends on practical manufacturing disclosure and proof.
Where is the “patent landscape” risk concentrated based on the claim architecture?
With only the claims text provided, the landscape analysis must be anchored to claim structure logic rather than specific citation mapping across other patents (which would require external bibliographic documents). Still, key landscape pressure points are identifiable:
Risk cluster 1: Broadness of Formula (I)
- The genus breadth (multiple variable positions across Ring A, Q pattern, R1/R2, and R3/R4/R8 functional classes) makes the patent a potential platform rather than a single lead series.
- Competitors developing “nearby” melanoma kinase-modulating or receptor-targeting small molecules would be at higher risk if they keep:
- the same core scaffold class,
- W as O or S,
- Het2 and heteroatom counts within the permitted ring sizes,
- the Q position N constraint pattern.
Risk cluster 2: Dependent claim fallback positioning
Dependent claims 2–6 and sub-formula claims 7–9 narrow the space in ways that often correspond to:
- “typical medicinal chemistry” choices (halo and small alkyl substituents; F/Cl at a key position),
- avoiding heteroatom placement that would violate the Q constraint (“not more than one N among Q1–Q4”).
Risk cluster 3: Therapeutic use is melanoma-specific
Method-of-use claims are tied to:
- melanoma (claim 11),
- V600E metastatic melanoma (claim 14).
Any competitor drug candidate targeting that specific patient population (or marketed for it) compounds enforceability leverage, assuming product structure matches claim 1’s Markush scope.
Landscape “hot spots” by claim category
Even without enumerating other US patents, the enforceability profile typically splits across three hot spots:
- Composition-of-matter (claim 1)
Highest leverage if accused compound matches the Markush genus.
- Method-of-use (claim 11/14)
Adds leverage when product labeling, clinical protocol, or marketing targets melanoma and especially V600E metastatic melanoma.
- Process claims (12/13)
Can deter reverse engineering of manufacturing if routes resemble the claimed intermediates/reactions.
Key takeaways
- US 8,415,345 is a broad chemical genus patent defined by Formula (I) with multiple independent substituent variables (a up to 3; multiple R1/R2/R3/R4/R8 classes; O vs S linker W; defined ring size/heteroatom constraints).
- The claim set includes composition-of-matter (claim 1), formulation (claim 10), melanoma method-of-use (claim 11), and V600E metastatic melanoma refinement (claim 14), plus process claims (12–13).
- Dependent claims (2–6, 7–9) carve out narrower structural subsets that can serve as fallback positions for infringement and validity defense, especially around:
- R1 substitution class,
- Ring A selection,
- Q-position heteroatom patterning,
- R2 class restriction,
- Q4 identity (notably C–F/C–Cl).
- The enforceability risk concentrates around compounds that match:
- the scaffold class defined by Formula (I),
- the heteroatom and ring-size constraints,
- and the melanoma/V600E use framing.
FAQs
1) Is US 8,415,345 limited to a single compound?
No. It claims a Markush genus under Formula (I) with many permissible substitutions and optional ring structures, plus salts.
2) What is the tightest disease-specific claim in the set?
Claim 14: metastatic melanoma with a mutation encoding a V600E amino acid substitution.
3) Which parts of the structure are most heavily constrained in dependent claims?
- R1 (claim 2),
- Ring A (claim 3),
- Q positions (claims 4 and 6),
- R2 (claim 5),
- Q4 (claims 6–9 sub-formulas).
4) Does the patent cover formulations?
Yes. Claim 10 covers pharmaceutical compositions containing a claim 1 compound and a pharmaceutically acceptable carrier/diluent/excipient.
5) Does it include manufacturing-route protection?
Yes. Claims 12 and 13 are process claims describing preparation of Formula (I) using defined intermediates and reaction types.
References
[1] US Patent 8,415,345, “Drug Patent,” claims 1–14 (provided claim text).
More… ↓
⤷ Start Trial
|
